Pharmaceutically acceptable salts of beta-guanidinopropionic acid with improved properties and uses thereof
AssigneeRgenix, Inc.
InventorsEduardo J. MARTINEZ, Andreas G. GRILL, Aniruddh SINGH, Padmini KAVURU
Life of this patent
Estimating the term…
Abstract
The present invention relates to new pharmaceutical salts of β-GPA which exhibit improved physical properties. In particular, the invention relates to salts of β-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of β-GPA, as well as methods of treating cancer including administration of a formulation including a β-GPA salt of the invention to a subject in need thereof.
Claims15
A method of treating cancer in a subject in need thereof, the method comprising administering an effective amount of a pharmaceutically acceptable salt of β-guanidinopropionic acid to the subject, wherein the pharmaceutically acceptable salt of β-guanidinopropionic acid is a 2:1 succinate salt, wherein the cancer is gastrointestinal, esophageal, colorectal, liver, pancreatic, or gastric cancer, or the cancer expresses CKB.
Dependencies are inferred from the claim text.